Ligand Pharma (LGND) Tops Q1 EPS by 30c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $298.50 --0%
Revenue Growth %: -32.2%
Financial Fact:
Weighted average number of common shares - basic: 20.89M
Today's EPS Names:
NEOV, MANU, CTAS, More
Revenue Growth %: -32.2%
Financial Fact:
Weighted average number of common shares - basic: 20.89M
Today's EPS Names:
NEOV, MANU, CTAS, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.97, $0.30 better than the analyst estimate of $0.67. Revenue for the quarter came in at $29.6 million versus the consensus estimate of $26.45 million.
GUIDANCE:
Ligand Pharma sees FY2016 EPS of $3.41-$3.46, versus the consensus of $3.37. Ligand Pharma sees FY2016 revenue of $115-119 million, versus the consensus of $118.5 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- Ligand pays $23M for royalty stake in pediatric myopia drug Ryjunea
- Sydnexis sells EMEA royalty rights to Ligand for $23 million
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
